| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Busulfan | 88 | 2024 | 766 | 15.150 |
Why?
|
| Transplantation Conditioning | 84 | 2023 | 2286 | 7.850 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 126 | 2024 | 6606 | 6.540 |
Why?
|
| Vidarabine | 42 | 2024 | 1347 | 6.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 22 | 2019 | 591 | 4.490 |
Why?
|
| Graft vs Host Disease | 76 | 2024 | 2734 | 3.580 |
Why?
|
| Leukemia, Myeloid, Acute | 59 | 2024 | 6932 | 3.540 |
Why?
|
| Adenine Nucleotides | 15 | 2016 | 351 | 3.170 |
Why?
|
| Transplantation, Homologous | 88 | 2021 | 2892 | 3.120 |
Why?
|
| Arabinonucleosides | 12 | 2016 | 437 | 2.850 |
Why?
|
| Cyclophosphamide | 49 | 2024 | 3080 | 2.770 |
Why?
|
| Melphalan | 26 | 2023 | 834 | 2.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 67 | 2023 | 15874 | 2.230 |
Why?
|
| Myeloablative Agonists | 18 | 2023 | 389 | 2.200 |
Why?
|
| Bone Marrow Transplantation | 61 | 2024 | 1638 | 1.940 |
Why?
|
| Hematologic Neoplasms | 25 | 2023 | 1901 | 1.860 |
Why?
|
| Myelodysplastic Syndromes | 27 | 2021 | 2982 | 1.730 |
Why?
|
| Deoxycytidine | 12 | 2020 | 1360 | 1.720 |
Why?
|
| Lymphoma | 17 | 2017 | 1471 | 1.660 |
Why?
|
| Hodgkin Disease | 15 | 2022 | 1435 | 1.520 |
Why?
|
| Stem Cell Transplantation | 19 | 2020 | 1367 | 1.510 |
Why?
|
| Immunosuppressive Agents | 27 | 2017 | 1416 | 1.440 |
Why?
|
| Depsipeptides | 4 | 2023 | 78 | 1.400 |
Why?
|
| Hydroxamic Acids | 7 | 2016 | 444 | 1.380 |
Why?
|
| Drug Synergism | 15 | 2022 | 1316 | 1.370 |
Why?
|
| Drug Monitoring | 7 | 2019 | 337 | 1.280 |
Why?
|
| Cladribine | 5 | 2024 | 233 | 1.250 |
Why?
|
| Epigenesis, Genetic | 4 | 2016 | 1397 | 1.220 |
Why?
|
| Thalassemia | 4 | 2022 | 26 | 1.170 |
Why?
|
| Humans | 351 | 2024 | 262269 | 1.170 |
Why?
|
| Leukemia, Myeloid | 19 | 2010 | 941 | 1.150 |
Why?
|
| DNA Damage | 14 | 2022 | 1947 | 1.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 27 | 2016 | 2525 | 1.060 |
Why?
|
| Hepatic Veno-Occlusive Disease | 4 | 2020 | 121 | 1.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2016 | 219 | 1.030 |
Why?
|
| Apoptosis | 16 | 2024 | 7601 | 1.000 |
Why?
|
| Multiple Myeloma | 12 | 2020 | 2152 | 0.960 |
Why?
|
| Adult | 203 | 2023 | 78181 | 0.950 |
Why?
|
| Middle Aged | 204 | 2023 | 86548 | 0.950 |
Why?
|
| Drug Interactions | 5 | 2018 | 555 | 0.950 |
Why?
|
| Antineoplastic Agents | 25 | 2022 | 14288 | 0.950 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2022 | 612 | 0.930 |
Why?
|
| Male | 228 | 2023 | 123347 | 0.890 |
Why?
|
| Sulfonamides | 5 | 2024 | 1826 | 0.890 |
Why?
|
| Cell Line, Tumor | 21 | 2024 | 14561 | 0.880 |
Why?
|
| Survival Analysis | 43 | 2021 | 9195 | 0.880 |
Why?
|
| Cystitis | 3 | 2021 | 107 | 0.870 |
Why?
|
| Cell Survival | 23 | 2017 | 3042 | 0.850 |
Why?
|
| Alkylating Agents | 2 | 2022 | 78 | 0.840 |
Why?
|
| Lymphoma, T-Cell | 2 | 2015 | 362 | 0.830 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2016 | 5183 | 0.820 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2020 | 2781 | 0.810 |
Why?
|
| Drug Combinations | 4 | 2024 | 621 | 0.800 |
Why?
|
| Virus Activation | 3 | 2019 | 228 | 0.780 |
Why?
|
| DNA Repair | 7 | 2022 | 1870 | 0.760 |
Why?
|
| Adolescent | 93 | 2021 | 31238 | 0.730 |
Why?
|
| Female | 210 | 2023 | 142305 | 0.730 |
Why?
|
| DNA, Viral | 4 | 2018 | 675 | 0.700 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2023 | 1765 | 0.700 |
Why?
|
| Transplantation, Autologous | 28 | 2023 | 1925 | 0.680 |
Why?
|
| Plasma | 1 | 2020 | 159 | 0.670 |
Why?
|
| HLA Antigens | 4 | 2017 | 563 | 0.670 |
Why?
|
| Reactive Oxygen Species | 3 | 2022 | 980 | 0.660 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 200 | 0.630 |
Why?
|
| Leukemia | 37 | 2010 | 1633 | 0.620 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 454 | 0.620 |
Why?
|
| Antigens, Neoplasm | 2 | 2023 | 1505 | 0.600 |
Why?
|
| Fluoresceins | 1 | 2017 | 73 | 0.600 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 24 | 0.590 |
Why?
|
| Membrane Potential, Mitochondrial | 4 | 2020 | 131 | 0.590 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2018 | 802 | 0.570 |
Why?
|
| Cell Proliferation | 5 | 2017 | 7241 | 0.570 |
Why?
|
| BK Virus | 4 | 2020 | 123 | 0.570 |
Why?
|
| Signal Transduction | 9 | 2020 | 11972 | 0.570 |
Why?
|
| Allografts | 13 | 2018 | 656 | 0.570 |
Why?
|
| Polyomavirus Infections | 4 | 2020 | 137 | 0.570 |
Why?
|
| Recurrence | 40 | 2023 | 4784 | 0.560 |
Why?
|
| Young Adult | 28 | 2021 | 21493 | 0.560 |
Why?
|
| Graft Survival | 17 | 2016 | 1071 | 0.560 |
Why?
|
| Metoprolol | 4 | 2003 | 28 | 0.560 |
Why?
|
| Transplantation, Haploidentical | 2 | 2022 | 140 | 0.550 |
Why?
|
| Tumor Virus Infections | 4 | 2020 | 217 | 0.550 |
Why?
|
| beta-Thalassemia | 1 | 2016 | 17 | 0.550 |
Why?
|
| Immunity, Cellular | 4 | 2017 | 419 | 0.550 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 923 | 0.540 |
Why?
|
| Hemorrhage | 3 | 2017 | 715 | 0.540 |
Why?
|
| Infusions, Intravenous | 12 | 2012 | 1379 | 0.530 |
Why?
|
| Aged | 108 | 2023 | 70370 | 0.530 |
Why?
|
| Pharmacogenetics | 2 | 2017 | 253 | 0.530 |
Why?
|
| Survival Rate | 43 | 2019 | 12239 | 0.530 |
Why?
|
| Disease-Free Survival | 37 | 2018 | 10021 | 0.520 |
Why?
|
| Phosphoramide Mustards | 5 | 2002 | 37 | 0.510 |
Why?
|
| Virus Diseases | 2 | 2018 | 399 | 0.510 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1350 | 0.510 |
Why?
|
| Child | 37 | 2022 | 29065 | 0.500 |
Why?
|
| Bortezomib | 2 | 2016 | 544 | 0.500 |
Why?
|
| Killer Cells, Natural | 3 | 2019 | 907 | 0.500 |
Why?
|
| Flow Cytometry | 8 | 2017 | 3022 | 0.490 |
Why?
|
| Myocardium | 7 | 1999 | 1295 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2018 | 4945 | 0.490 |
Why?
|
| Tumor Cells, Cultured | 19 | 2017 | 5378 | 0.490 |
Why?
|
| Azacitidine | 5 | 2016 | 1149 | 0.480 |
Why?
|
| Thiotepa | 10 | 2024 | 118 | 0.480 |
Why?
|
| Chimerism | 1 | 2014 | 65 | 0.470 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2023 | 1667 | 0.470 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 499 | 0.470 |
Why?
|
| Heart Transplantation | 6 | 2016 | 885 | 0.470 |
Why?
|
| Indoles | 2 | 2016 | 1011 | 0.460 |
Why?
|
| T-Lymphocytes | 17 | 2022 | 3878 | 0.450 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2020 | 566 | 0.430 |
Why?
|
| Remission Induction | 26 | 2020 | 3585 | 0.430 |
Why?
|
| Salvage Therapy | 8 | 2018 | 2059 | 0.430 |
Why?
|
| Follow-Up Studies | 36 | 2019 | 14914 | 0.430 |
Why?
|
| Niacinamide | 1 | 2014 | 421 | 0.430 |
Why?
|
| Histocompatibility Testing | 11 | 2018 | 467 | 0.420 |
Why?
|
| Daunorubicin | 11 | 2016 | 302 | 0.420 |
Why?
|
| Microbiota | 1 | 2018 | 543 | 0.420 |
Why?
|
| Prognosis | 41 | 2020 | 21737 | 0.410 |
Why?
|
| Treatment Outcome | 57 | 2021 | 33028 | 0.400 |
Why?
|
| Bayes Theorem | 4 | 2022 | 1034 | 0.400 |
Why?
|
| DNA Methylation | 3 | 2018 | 2671 | 0.400 |
Why?
|
| Lymphoma, Non-Hodgkin | 14 | 2010 | 1041 | 0.400 |
Why?
|
| Drug Administration Schedule | 16 | 2015 | 3482 | 0.400 |
Why?
|
| Neoplasms | 11 | 2023 | 15180 | 0.400 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3233 | 0.390 |
Why?
|
| Amsacrine | 11 | 1990 | 61 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 10067 | 0.390 |
Why?
|
| Etoposide | 15 | 2018 | 873 | 0.380 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 581 | 0.380 |
Why?
|
| Metronidazole | 1 | 2011 | 151 | 0.370 |
Why?
|
| Injections, Intravenous | 10 | 2011 | 576 | 0.370 |
Why?
|
| Calcineurin Inhibitors | 3 | 2016 | 69 | 0.370 |
Why?
|
| Everolimus | 4 | 2017 | 415 | 0.370 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2003 | 324 | 0.370 |
Why?
|
| Heart Failure | 10 | 2014 | 2523 | 0.370 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2016 | 560 | 0.370 |
Why?
|
| Hematopoietic Stem Cells | 14 | 2015 | 1236 | 0.360 |
Why?
|
| Cross-Linking Reagents | 1 | 2010 | 153 | 0.360 |
Why?
|
| Administration, Oral | 8 | 2020 | 1554 | 0.350 |
Why?
|
| Aldehyde Dehydrogenase | 3 | 2002 | 105 | 0.350 |
Why?
|
| Lymphocyte Depletion | 6 | 2018 | 269 | 0.350 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2016 | 363 | 0.350 |
Why?
|
| Genes, cdc | 1 | 2009 | 80 | 0.350 |
Why?
|
| Cytarabine | 18 | 2018 | 1976 | 0.340 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2003 | 237 | 0.340 |
Why?
|
| Retrospective Studies | 49 | 2024 | 38022 | 0.340 |
Why?
|
| Drug Therapy, Combination | 15 | 2015 | 2325 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2014 | 1826 | 0.340 |
Why?
|
| Antilymphocyte Serum | 9 | 2013 | 230 | 0.340 |
Why?
|
| Whole-Body Irradiation | 9 | 2016 | 312 | 0.330 |
Why?
|
| Area Under Curve | 5 | 2020 | 699 | 0.330 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 1997 | 558 | 0.330 |
Why?
|
| Acute Disease | 25 | 2018 | 2431 | 0.330 |
Why?
|
| Hematologic Diseases | 4 | 2020 | 241 | 0.330 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2010 | 367 | 0.320 |
Why?
|
| Child, Preschool | 21 | 2020 | 16213 | 0.310 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2023 | 1145 | 0.310 |
Why?
|
| Phthalazines | 2 | 2022 | 253 | 0.310 |
Why?
|
| Prospective Studies | 21 | 2024 | 12923 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 8 | 2016 | 2480 | 0.310 |
Why?
|
| Nucleosides | 2 | 2022 | 60 | 0.300 |
Why?
|
| Genomic Library | 3 | 1998 | 41 | 0.300 |
Why?
|
| Tacrolimus | 8 | 2010 | 342 | 0.300 |
Why?
|
| Infant | 17 | 2020 | 13285 | 0.300 |
Why?
|
| Caspases | 3 | 2022 | 662 | 0.300 |
Why?
|
| DNA | 15 | 2022 | 2683 | 0.300 |
Why?
|
| Cloning, Molecular | 6 | 1997 | 1208 | 0.290 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2011 | 1759 | 0.290 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2017 | 85 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 1596 | 0.280 |
Why?
|
| Cytotoxins | 2 | 2020 | 65 | 0.280 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2015 | 427 | 0.280 |
Why?
|
| Ethers, Cyclic | 1 | 2006 | 16 | 0.280 |
Why?
|
| Philadelphia Chromosome | 4 | 2011 | 792 | 0.280 |
Why?
|
| Chromosome Aberrations | 12 | 2020 | 1957 | 0.280 |
Why?
|
| Sweden | 11 | 2016 | 70 | 0.280 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2022 | 170 | 0.280 |
Why?
|
| Bone Marrow Purging | 5 | 2011 | 86 | 0.270 |
Why?
|
| Viral Load | 2 | 2018 | 492 | 0.270 |
Why?
|
| Incidence | 12 | 2020 | 5713 | 0.270 |
Why?
|
| DNA, Complementary | 3 | 1997 | 870 | 0.270 |
Why?
|
| Benzofurans | 1 | 2006 | 38 | 0.270 |
Why?
|
| Sirolimus | 4 | 2017 | 818 | 0.270 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 482 | 0.270 |
Why?
|
| Benzoates | 2 | 2024 | 133 | 0.260 |
Why?
|
| Fetal Blood | 3 | 2015 | 480 | 0.260 |
Why?
|
| Phosphorylation | 4 | 2022 | 4809 | 0.260 |
Why?
|
| Time Factors | 26 | 2020 | 12985 | 0.260 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2053 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 1493 | 0.260 |
Why?
|
| Chromatin | 2 | 2022 | 950 | 0.250 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 10 | 2009 | 749 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 1040 | 0.250 |
Why?
|
| Blood Transfusion | 5 | 2006 | 585 | 0.250 |
Why?
|
| Piperazines | 5 | 2022 | 2098 | 0.250 |
Why?
|
| Caspase 3 | 2 | 2022 | 469 | 0.250 |
Why?
|
| Cell Membrane Permeability | 2 | 2016 | 122 | 0.250 |
Why?
|
| Bone Marrow | 11 | 2020 | 2360 | 0.250 |
Why?
|
| Potassium | 1 | 2006 | 330 | 0.250 |
Why?
|
| Animals | 55 | 2021 | 59486 | 0.250 |
Why?
|
| Doxorubicin | 10 | 2009 | 3005 | 0.250 |
Why?
|
| Hydrazines | 2 | 2024 | 208 | 0.250 |
Why?
|
| Methylprednisolone | 3 | 2009 | 193 | 0.240 |
Why?
|
| Neoplasm, Residual | 5 | 2018 | 1668 | 0.240 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 4787 | 0.240 |
Why?
|
| Base Sequence | 16 | 2013 | 4886 | 0.240 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2016 | 724 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 3550 | 0.240 |
Why?
|
| Graft Rejection | 4 | 2016 | 834 | 0.230 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2016 | 289 | 0.230 |
Why?
|
| Postoperative Complications | 3 | 2017 | 5568 | 0.230 |
Why?
|
| Cell Separation | 7 | 2011 | 610 | 0.230 |
Why?
|
| Cyclosporine | 6 | 2016 | 282 | 0.220 |
Why?
|
| Administration, Intravenous | 2 | 2023 | 249 | 0.220 |
Why?
|
| Poly ADP Ribosylation | 1 | 2022 | 9 | 0.220 |
Why?
|
| Vascular Diseases | 2 | 2016 | 246 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 10 | 2017 | 3189 | 0.220 |
Why?
|
| Heart Rate | 5 | 1999 | 739 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1684 | 0.210 |
Why?
|
| Hematopoiesis | 8 | 1998 | 561 | 0.210 |
Why?
|
| Tissue Donors | 9 | 2008 | 790 | 0.210 |
Why?
|
| Histones | 3 | 2016 | 1462 | 0.210 |
Why?
|
| Risk Factors | 22 | 2018 | 17622 | 0.210 |
Why?
|
| Anthracenes | 1 | 2022 | 48 | 0.210 |
Why?
|
| Heart | 3 | 2003 | 1227 | 0.210 |
Why?
|
| Thrombocytopenia | 3 | 2021 | 847 | 0.210 |
Why?
|
| Myocardial Ischemia | 2 | 2003 | 433 | 0.210 |
Why?
|
| Graft vs Host Reaction | 8 | 1998 | 63 | 0.210 |
Why?
|
| Methotrexate | 8 | 2010 | 1002 | 0.200 |
Why?
|
| Ventricular Remodeling | 1 | 2003 | 245 | 0.200 |
Why?
|
| Chlorambucil | 2 | 2017 | 26 | 0.200 |
Why?
|
| Rats | 22 | 1999 | 6107 | 0.200 |
Why?
|
| Stroke Volume | 2 | 2003 | 575 | 0.200 |
Why?
|
| Combined Modality Therapy | 27 | 2019 | 8885 | 0.200 |
Why?
|
| Rabbits | 7 | 2010 | 958 | 0.200 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1221 | 0.200 |
Why?
|
| Cytomegalovirus | 3 | 2019 | 474 | 0.200 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Ifosfamide | 4 | 2009 | 346 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 8882 | 0.190 |
Why?
|
| Genetic Markers | 6 | 2003 | 972 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 51 | 0.190 |
Why?
|
| STAT5 Transcription Factor | 1 | 2022 | 215 | 0.190 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 34 | 0.190 |
Why?
|
| Molecular Sequence Data | 18 | 2000 | 6062 | 0.190 |
Why?
|
| Carmustine | 5 | 2018 | 214 | 0.190 |
Why?
|
| Ethanol | 3 | 1995 | 265 | 0.190 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 274 | 0.190 |
Why?
|
| Blood Platelets | 4 | 2015 | 730 | 0.190 |
Why?
|
| Transplantation Chimera | 7 | 2015 | 163 | 0.180 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 541 | 0.180 |
Why?
|
| Antigens, CD34 | 4 | 2018 | 593 | 0.180 |
Why?
|
| Cosmids | 3 | 1999 | 40 | 0.180 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2006 | 1093 | 0.180 |
Why?
|
| Mitochondria, Liver | 4 | 1987 | 49 | 0.180 |
Why?
|
| DNA Fragmentation | 1 | 2020 | 196 | 0.180 |
Why?
|
| Anthraquinones | 1 | 1999 | 27 | 0.170 |
Why?
|
| Bacteriophage M13 | 2 | 1996 | 15 | 0.170 |
Why?
|
| Exercise Test | 2 | 2003 | 306 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 3632 | 0.170 |
Why?
|
| Immunologic Memory | 2 | 2023 | 374 | 0.170 |
Why?
|
| Blast Crisis | 9 | 2006 | 557 | 0.170 |
Why?
|
| Transplant Recipients | 3 | 2020 | 322 | 0.170 |
Why?
|
| Intracellular Membranes | 5 | 2016 | 107 | 0.170 |
Why?
|
| Cardiac Output, High | 1 | 1999 | 4 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2014 | 1294 | 0.170 |
Why?
|
| DNA Primers | 7 | 2013 | 1395 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 2 | 2011 | 232 | 0.170 |
Why?
|
| Critical Care | 2 | 2011 | 779 | 0.170 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 403 | 0.170 |
Why?
|
| Interferon-gamma | 9 | 2006 | 1148 | 0.170 |
Why?
|
| Torque teno virus | 1 | 2018 | 2 | 0.170 |
Why?
|
| Biological Transport | 3 | 2017 | 598 | 0.170 |
Why?
|
| Blood Component Removal | 2 | 2016 | 122 | 0.170 |
Why?
|
| Leukocyte Transfusion | 4 | 2012 | 43 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 1993 | 410 | 0.170 |
Why?
|
| Vagus Nerve | 1 | 1999 | 63 | 0.170 |
Why?
|
| DNA Virus Infections | 1 | 2018 | 29 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 2992 | 0.160 |
Why?
|
| Genome, Protozoan | 1 | 1998 | 27 | 0.160 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 83 | 0.160 |
Why?
|
| Cardiac Output, Low | 1 | 1999 | 81 | 0.160 |
Why?
|
| Thymus Neoplasms | 2 | 2023 | 402 | 0.160 |
Why?
|
| Radiation Tolerance | 1 | 2002 | 629 | 0.160 |
Why?
|
| X Chromosome | 3 | 1999 | 337 | 0.160 |
Why?
|
| Pyrazoles | 3 | 2024 | 1479 | 0.160 |
Why?
|
| Infant, Newborn | 4 | 2020 | 8225 | 0.160 |
Why?
|
| Oxygen Consumption | 6 | 1999 | 398 | 0.160 |
Why?
|
| Primary Myelofibrosis | 2 | 2020 | 831 | 0.150 |
Why?
|
| beta Catenin | 1 | 2022 | 687 | 0.150 |
Why?
|
| Mitochondria | 2 | 2016 | 1281 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 83 | 0.150 |
Why?
|
| Open Reading Frames | 1 | 1998 | 248 | 0.150 |
Why?
|
| Ethacrynic Acid | 1 | 2017 | 9 | 0.150 |
Why?
|
| fas Receptor | 1 | 1998 | 185 | 0.150 |
Why?
|
| Peroxides | 2 | 1996 | 12 | 0.150 |
Why?
|
| Ketoconazole | 1 | 2017 | 34 | 0.150 |
Why?
|
| Cell Line | 18 | 2002 | 5071 | 0.150 |
Why?
|
| Tandem Repeat Sequences | 2 | 2016 | 201 | 0.150 |
Why?
|
| Unrelated Donors | 2 | 2016 | 319 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 579 | 0.150 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2009 | 446 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1999 | 249 | 0.150 |
Why?
|
| Hemodynamics | 4 | 1999 | 944 | 0.150 |
Why?
|
| Sorbitol | 2 | 1995 | 28 | 0.150 |
Why?
|
| Cell Death | 2 | 2016 | 672 | 0.150 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 1999 | 81 | 0.150 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 11 | 0.150 |
Why?
|
| Cytogenetics | 2 | 2014 | 149 | 0.150 |
Why?
|
| Age Factors | 10 | 2015 | 5384 | 0.150 |
Why?
|
| Adenoviridae Infections | 1 | 2017 | 123 | 0.150 |
Why?
|
| Homozygote | 2 | 2016 | 714 | 0.150 |
Why?
|
| Coronary Disease | 2 | 1995 | 769 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2015 | 3529 | 0.140 |
Why?
|
| Templates, Genetic | 1 | 1996 | 86 | 0.140 |
Why?
|
| Genes, p53 | 2 | 2018 | 1093 | 0.140 |
Why?
|
| Hypoxia | 4 | 1987 | 448 | 0.140 |
Why?
|
| Photosynthetic Reaction Center Complex Proteins | 1 | 1996 | 2 | 0.140 |
Why?
|
| Hemoglobin E | 1 | 2016 | 1 | 0.140 |
Why?
|
| Chloroplasts | 1 | 1996 | 15 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2016 | 78 | 0.140 |
Why?
|
| Comorbidity | 2 | 2023 | 2397 | 0.140 |
Why?
|
| Gene Duplication | 1 | 2018 | 421 | 0.140 |
Why?
|
| Carboprost | 1 | 1995 | 4 | 0.140 |
Why?
|
| Receptors, KIR | 1 | 2016 | 62 | 0.140 |
Why?
|
| Immunologic Techniques | 1 | 1995 | 42 | 0.140 |
Why?
|
| Aflatoxins | 1 | 1995 | 13 | 0.140 |
Why?
|
| Consensus | 1 | 2020 | 1005 | 0.140 |
Why?
|
| Blood | 1 | 2016 | 156 | 0.140 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2016 | 51 | 0.130 |
Why?
|
| Mannitol | 1 | 1995 | 54 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1016 | 0.130 |
Why?
|
| Tissue Extracts | 1 | 1995 | 47 | 0.130 |
Why?
|
| Aspergillosis | 3 | 2001 | 246 | 0.130 |
Why?
|
| Liver | 9 | 2005 | 2904 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 4355 | 0.130 |
Why?
|
| Life Tables | 3 | 1994 | 120 | 0.130 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 2 | 1992 | 29 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 5 | 1999 | 2073 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 5 | 2009 | 4386 | 0.130 |
Why?
|
| Histone Code | 1 | 2016 | 79 | 0.130 |
Why?
|
| Therapeutic Irrigation | 1 | 1995 | 90 | 0.130 |
Why?
|
| Consolidation Chemotherapy | 1 | 2016 | 154 | 0.130 |
Why?
|
| Trypanosoma cruzi | 1 | 1998 | 222 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 128 | 0.130 |
Why?
|
| CHO Cells | 1 | 1996 | 310 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 120 | 0.130 |
Why?
|
| N-Glycosyl Hydrolases | 2 | 1996 | 48 | 0.130 |
Why?
|
| Power Plants | 1 | 1995 | 4 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 | 2004 | 2393 | 0.130 |
Why?
|
| Chromosome Mapping | 4 | 2003 | 1464 | 0.130 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1995 | 24 | 0.130 |
Why?
|
| Fucose | 1 | 2015 | 51 | 0.130 |
Why?
|
| Minisatellite Repeats | 1 | 1995 | 51 | 0.130 |
Why?
|
| Neonatal Screening | 1 | 2016 | 165 | 0.130 |
Why?
|
| Acetamides | 3 | 2023 | 112 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 1995 | 104 | 0.130 |
Why?
|
| Adenosine | 2 | 2001 | 291 | 0.130 |
Why?
|
| Oncogene Proteins | 2 | 1999 | 356 | 0.130 |
Why?
|
| Genes | 1 | 1996 | 480 | 0.120 |
Why?
|
| Alleles | 5 | 2016 | 2434 | 0.120 |
Why?
|
| Maintenance Chemotherapy | 1 | 2015 | 202 | 0.120 |
Why?
|
| Neutrophils | 3 | 2015 | 834 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2011 | 4768 | 0.120 |
Why?
|
| Angiotensin II | 1 | 1995 | 195 | 0.120 |
Why?
|
| Cardiotonic Agents | 1 | 1995 | 155 | 0.120 |
Why?
|
| Salmon | 1 | 2014 | 7 | 0.120 |
Why?
|
| Carcinogens | 1 | 1995 | 383 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 762 | 0.120 |
Why?
|
| Food Contamination | 1 | 2014 | 22 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 337 | 0.120 |
Why?
|
| Tumor Protein p73 | 1 | 2014 | 105 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 1995 | 205 | 0.120 |
Why?
|
| Drug Resistance | 11 | 2005 | 588 | 0.120 |
Why?
|
| Listeriosis | 1 | 2014 | 35 | 0.120 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 37 | 0.120 |
Why?
|
| DNA Glycosylases | 1 | 1994 | 92 | 0.120 |
Why?
|
| Listeria monocytogenes | 1 | 2014 | 52 | 0.120 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 358 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 1999 | 453 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 6047 | 0.120 |
Why?
|
| Glycine | 1 | 1995 | 289 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2009 | 265 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1993 | 97 | 0.110 |
Why?
|
| Heart Diseases | 3 | 2016 | 738 | 0.110 |
Why?
|
| Diastole | 1 | 1993 | 185 | 0.110 |
Why?
|
| Neutropenia | 6 | 2015 | 965 | 0.110 |
Why?
|
| Recombinant Proteins | 15 | 2009 | 2914 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 3 | 1999 | 2485 | 0.110 |
Why?
|
| Karyotyping | 9 | 1995 | 1017 | 0.110 |
Why?
|
| RNA, Messenger | 6 | 2016 | 6129 | 0.110 |
Why?
|
| Biotransformation | 6 | 2002 | 93 | 0.110 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 1985 | 212 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 1995 | 1054 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2017 | 1432 | 0.100 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2012 | 126 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 1541 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2018 | 1129 | 0.100 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2012 | 35 | 0.100 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1992 | 72 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 3 | 1997 | 68 | 0.100 |
Why?
|
| Lymphocytes | 7 | 1992 | 1227 | 0.100 |
Why?
|
| Half-Life | 2 | 2011 | 258 | 0.100 |
Why?
|
| Histocompatibility | 4 | 2011 | 182 | 0.100 |
Why?
|
| In Vitro Techniques | 10 | 1992 | 1613 | 0.100 |
Why?
|
| Biological Availability | 2 | 2003 | 225 | 0.100 |
Why?
|
| Kinetics | 12 | 1996 | 2041 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 386 | 0.100 |
Why?
|
| Cytogenetic Analysis | 3 | 2020 | 564 | 0.100 |
Why?
|
| Kidney Diseases | 2 | 2016 | 692 | 0.100 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2010 | 24 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 204 | 0.100 |
Why?
|
| Agranulocytosis | 1 | 1990 | 79 | 0.100 |
Why?
|
| Imines | 1 | 1990 | 14 | 0.090 |
Why?
|
| Quinones | 1 | 1990 | 21 | 0.090 |
Why?
|
| Drugs, Generic | 1 | 2010 | 35 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2018 | 1162 | 0.090 |
Why?
|
| Pentostatin | 1 | 2010 | 120 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2860 | 0.090 |
Why?
|
| Coronary Artery Bypass | 1 | 1995 | 708 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 869 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2011 | 111 | 0.090 |
Why?
|
| Polyethylene Glycols | 4 | 2000 | 621 | 0.090 |
Why?
|
| Intercalating Agents | 2 | 1987 | 29 | 0.090 |
Why?
|
| Acetylation | 1 | 2011 | 511 | 0.090 |
Why?
|
| Thalidomide | 2 | 2015 | 570 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 334 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2017 | 1234 | 0.090 |
Why?
|
| Hospitalization | 2 | 2004 | 2119 | 0.090 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 278 | 0.090 |
Why?
|
| Prostate | 1 | 1995 | 1090 | 0.090 |
Why?
|
| Ganciclovir | 3 | 1997 | 175 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.090 |
Why?
|
| Benzoquinones | 1 | 1990 | 108 | 0.090 |
Why?
|
| Acetaminophen | 2 | 1982 | 116 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2018 | 2089 | 0.090 |
Why?
|
| Living Donors | 1 | 2010 | 176 | 0.090 |
Why?
|
| Cytosol | 4 | 1996 | 237 | 0.090 |
Why?
|
| Nutrition Disorders | 1 | 1990 | 57 | 0.090 |
Why?
|
| RNA Splicing | 1 | 1992 | 369 | 0.090 |
Why?
|
| Gated Blood-Pool Imaging | 2 | 2003 | 17 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2015 | 9283 | 0.090 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 304 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2006 | 706 | 0.090 |
Why?
|
| Feasibility Studies | 7 | 2023 | 2302 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2008 | 5155 | 0.090 |
Why?
|
| Blood Group Antigens | 1 | 1990 | 91 | 0.090 |
Why?
|
| Glutamine | 1 | 2011 | 300 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2288 | 0.090 |
Why?
|
| Cell Culture Techniques | 2 | 2012 | 598 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 363 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2016 | 924 | 0.080 |
Why?
|
| Genotype | 2 | 2016 | 4104 | 0.080 |
Why?
|
| Respiratory Insufficiency | 2 | 1990 | 332 | 0.080 |
Why?
|
| Lung Diseases | 3 | 2001 | 721 | 0.080 |
Why?
|
| Drug Stability | 3 | 1997 | 106 | 0.080 |
Why?
|
| HLA-DQ Antigens | 2 | 2000 | 59 | 0.080 |
Why?
|
| Measles virus | 2 | 1999 | 14 | 0.080 |
Why?
|
| HLA-DR Antigens | 2 | 2000 | 173 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1305 | 0.080 |
Why?
|
| Solvents | 3 | 2000 | 66 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2062 | 0.080 |
Why?
|
| Cells, Cultured | 9 | 2008 | 5597 | 0.080 |
Why?
|
| Pyrimidines | 4 | 2009 | 3538 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 495 | 0.080 |
Why?
|
| Ethylenediamines | 1 | 2008 | 21 | 0.080 |
Why?
|
| HIV-1 | 1 | 1993 | 649 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 130 | 0.080 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2000 | 186 | 0.080 |
Why?
|
| Solubility | 3 | 1997 | 246 | 0.080 |
Why?
|
| Receptors, Angiotensin | 2 | 1999 | 44 | 0.080 |
Why?
|
| Glutathione | 4 | 2002 | 364 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2009 | 148 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 3 | 2016 | 603 | 0.080 |
Why?
|
| Amphotericin B | 4 | 2001 | 289 | 0.080 |
Why?
|
| Nutritional Status | 1 | 1990 | 338 | 0.080 |
Why?
|
| G2 Phase | 1 | 2008 | 206 | 0.080 |
Why?
|
| Imides | 1 | 1987 | 10 | 0.070 |
Why?
|
| Chelating Agents | 1 | 2008 | 130 | 0.070 |
Why?
|
| Phenetidine | 2 | 1985 | 2 | 0.070 |
Why?
|
| Bone Marrow Cells | 11 | 1999 | 939 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 3 | 2004 | 178 | 0.070 |
Why?
|
| Verapamil | 1 | 1987 | 79 | 0.070 |
Why?
|
| Aminophenols | 2 | 1985 | 12 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 4 | 1995 | 1439 | 0.070 |
Why?
|
| Energy Metabolism | 2 | 1990 | 994 | 0.070 |
Why?
|
| Graft vs Tumor Effect | 2 | 2004 | 140 | 0.070 |
Why?
|
| Aminoglycosides | 1 | 2007 | 220 | 0.070 |
Why?
|
| Copper | 1 | 2008 | 167 | 0.070 |
Why?
|
| Gene Library | 3 | 1997 | 293 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2004 | 1540 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 1997 | 586 | 0.070 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 196 | 0.070 |
Why?
|
| Isoquinolines | 1 | 1987 | 116 | 0.070 |
Why?
|
| Immune Tolerance | 2 | 2006 | 405 | 0.070 |
Why?
|
| Interleukin-6 | 5 | 1995 | 1031 | 0.070 |
Why?
|
| Hepatectomy | 1 | 2013 | 1009 | 0.070 |
Why?
|
| Radioimmunotherapy | 2 | 1997 | 120 | 0.070 |
Why?
|
| Ions | 2 | 1987 | 54 | 0.070 |
Why?
|
| Social Security | 1 | 2006 | 3 | 0.070 |
Why?
|
| Rehabilitation, Vocational | 1 | 2006 | 8 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 323 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2012 | 980 | 0.070 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2012 | 37 | 0.070 |
Why?
|
| Retroviridae | 4 | 1993 | 323 | 0.070 |
Why?
|
| Water | 3 | 1997 | 364 | 0.070 |
Why?
|
| Cytokines | 5 | 2005 | 2824 | 0.070 |
Why?
|
| Idarubicin | 4 | 2000 | 446 | 0.070 |
Why?
|
| Gene Expression | 2 | 2009 | 3563 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2009 | 475 | 0.070 |
Why?
|
| Mitoxantrone | 4 | 1999 | 217 | 0.070 |
Why?
|
| Risk Assessment | 5 | 2020 | 6900 | 0.070 |
Why?
|
| Blood Cell Count | 5 | 2012 | 225 | 0.070 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2005 | 9 | 0.070 |
Why?
|
| Lorazepam | 1 | 1986 | 40 | 0.070 |
Why?
|
| Age Distribution | 3 | 2014 | 703 | 0.070 |
Why?
|
| Granulocytes | 7 | 1997 | 223 | 0.070 |
Why?
|
| Immunophenotyping | 6 | 2016 | 1684 | 0.070 |
Why?
|
| Peroxidases | 2 | 1983 | 29 | 0.070 |
Why?
|
| Rituximab | 3 | 2023 | 1534 | 0.070 |
Why?
|
| Filgrastim | 6 | 2009 | 192 | 0.070 |
Why?
|
| Ferritins | 2 | 2014 | 152 | 0.070 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 5009 | 0.070 |
Why?
|
| Th1 Cells | 2 | 2016 | 252 | 0.070 |
Why?
|
| Digitonin | 1 | 1985 | 4 | 0.070 |
Why?
|
| Adenosine Triphosphate | 3 | 1996 | 573 | 0.070 |
Why?
|
| Antigens, CD | 5 | 2007 | 1382 | 0.070 |
Why?
|
| Haloperidol | 1 | 1986 | 65 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 194 | 0.070 |
Why?
|
| Lipid Peroxidation | 2 | 1996 | 154 | 0.060 |
Why?
|
| Neurocognitive Disorders | 1 | 1986 | 69 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 1996 | 2811 | 0.060 |
Why?
|
| Photopheresis | 1 | 2005 | 79 | 0.060 |
Why?
|
| Employment | 1 | 2006 | 127 | 0.060 |
Why?
|
| Genetic Vectors | 3 | 1996 | 1681 | 0.060 |
Why?
|
| Mycoses | 3 | 2004 | 386 | 0.060 |
Why?
|
| CD8 Antigens | 4 | 1992 | 170 | 0.060 |
Why?
|
| Antifungal Agents | 4 | 2001 | 840 | 0.060 |
Why?
|
| Herpes Simplex | 1 | 2005 | 94 | 0.060 |
Why?
|
| Leukemia, Lymphoid | 2 | 1985 | 276 | 0.060 |
Why?
|
| Point Mutation | 2 | 2006 | 769 | 0.060 |
Why?
|
| Cell Division | 8 | 1995 | 2467 | 0.060 |
Why?
|
| Mutation | 6 | 2017 | 15167 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2011 | 2605 | 0.060 |
Why?
|
| Interleukin-1 | 4 | 1996 | 455 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2008 | 1760 | 0.060 |
Why?
|
| Texas | 2 | 2012 | 6308 | 0.060 |
Why?
|
| CD4 Antigens | 2 | 2016 | 170 | 0.060 |
Why?
|
| Emergencies | 1 | 1986 | 206 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2010 | 1529 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6223 | 0.060 |
Why?
|
| DNA Topoisomerases, Type II | 4 | 1990 | 117 | 0.060 |
Why?
|
| Histocompatibility Antigens | 2 | 1974 | 74 | 0.060 |
Why?
|
| NADP | 2 | 1996 | 96 | 0.060 |
Why?
|
| Patient Selection | 4 | 2006 | 2063 | 0.060 |
Why?
|
| Microscopy, Electron | 5 | 1996 | 591 | 0.060 |
Why?
|
| Harmine | 2 | 1980 | 3 | 0.060 |
Why?
|
| Pinus sylvestris | 1 | 2003 | 1 | 0.060 |
Why?
|
| Risk | 3 | 2017 | 1974 | 0.060 |
Why?
|
| Chronic Disease | 7 | 2005 | 1850 | 0.060 |
Why?
|
| Postmortem Changes | 1 | 1983 | 14 | 0.060 |
Why?
|
| Blood Donors | 3 | 2012 | 165 | 0.060 |
Why?
|
| Electrophoresis | 2 | 1993 | 60 | 0.060 |
Why?
|
| Leukapheresis | 2 | 2009 | 152 | 0.060 |
Why?
|
| Translocation, Genetic | 3 | 2000 | 1244 | 0.060 |
Why?
|
| Delirium | 1 | 1986 | 207 | 0.060 |
Why?
|
| Cardiomyopathies | 2 | 1993 | 601 | 0.060 |
Why?
|
| Hydrogen Peroxide | 2 | 1983 | 216 | 0.050 |
Why?
|
| Thiazoles | 1 | 2007 | 727 | 0.050 |
Why?
|
| Rhodamines | 2 | 2016 | 49 | 0.050 |
Why?
|
| Cisplatin | 5 | 1999 | 2432 | 0.050 |
Why?
|
| Leukemia, Experimental | 2 | 1981 | 78 | 0.050 |
Why?
|
| Social Support | 1 | 2006 | 569 | 0.050 |
Why?
|
| Vincristine | 2 | 2009 | 1508 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1990 | 962 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 3317 | 0.050 |
Why?
|
| Erythropoiesis | 2 | 1973 | 74 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 1999 | 1448 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1999 | 591 | 0.050 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 600 | 0.050 |
Why?
|
| Prednimustine | 1 | 1982 | 1 | 0.050 |
Why?
|
| Chemistry | 3 | 1991 | 99 | 0.050 |
Why?
|
| Chemical Phenomena | 3 | 1991 | 137 | 0.050 |
Why?
|
| Brain | 1 | 1995 | 4097 | 0.050 |
Why?
|
| Multivariate Analysis | 5 | 2007 | 4323 | 0.050 |
Why?
|
| Thioguanine | 1 | 1982 | 68 | 0.050 |
Why?
|
| Pilot Projects | 8 | 2008 | 2804 | 0.050 |
Why?
|
| Mycophenolic Acid | 2 | 2014 | 149 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2017 | 1393 | 0.050 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2002 | 70 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2004 | 269 | 0.050 |
Why?
|
| Spleen | 7 | 1975 | 674 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 3 | 1999 | 64 | 0.050 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 3755 | 0.050 |
Why?
|
| Sarcoma, Experimental | 2 | 1992 | 68 | 0.050 |
Why?
|
| Immunoglobulins | 3 | 1996 | 267 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 637 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 13669 | 0.050 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2003 | 180 | 0.050 |
Why?
|
| Probability | 2 | 2004 | 868 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 1122 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1990 | 410 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1998 | 348 | 0.050 |
Why?
|
| Antigens, Viral | 3 | 1999 | 467 | 0.050 |
Why?
|
| Indium Radioisotopes | 2 | 1997 | 65 | 0.050 |
Why?
|
| Cell Hypoxia | 1 | 2002 | 329 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 1981 | 57 | 0.050 |
Why?
|
| Gamma Rays | 1 | 2002 | 242 | 0.050 |
Why?
|
| Mitochondria, Heart | 2 | 1996 | 73 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 480 | 0.050 |
Why?
|
| Foscarnet | 2 | 1997 | 17 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 357 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 4563 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 1984 | 412 | 0.050 |
Why?
|
| Aspergillus fumigatus | 1 | 2001 | 136 | 0.050 |
Why?
|
| Oncogenes | 3 | 1989 | 669 | 0.050 |
Why?
|
| Germinal Center | 1 | 2021 | 165 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 2 | 1996 | 72 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 2504 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 1981 | 148 | 0.040 |
Why?
|
| Cause of Death | 2 | 2012 | 757 | 0.040 |
Why?
|
| Exons | 3 | 1993 | 1325 | 0.040 |
Why?
|
| Carubicin | 1 | 1999 | 2 | 0.040 |
Why?
|
| H-2 Antigens | 1 | 1979 | 39 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2000 | 170 | 0.040 |
Why?
|
| Alkaloids | 1 | 1979 | 79 | 0.040 |
Why?
|
| Echocardiography | 2 | 1996 | 1189 | 0.040 |
Why?
|
| Cell Differentiation | 8 | 2023 | 4042 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 2 | 1997 | 178 | 0.040 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 10348 | 0.040 |
Why?
|
| Perfusion | 2 | 1996 | 294 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 1984 | 530 | 0.040 |
Why?
|
| NAD | 2 | 1996 | 89 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1997 | 260 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 12 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2005 | 1991 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 198 | 0.040 |
Why?
|
| Epirubicin | 1 | 1999 | 157 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 1980 | 745 | 0.040 |
Why?
|
| DNA, Neoplasm | 4 | 1992 | 1905 | 0.040 |
Why?
|
| Cell Size | 1 | 1999 | 135 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 2000 | 215 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1999 | 66 | 0.040 |
Why?
|
| Bacterial Infections | 2 | 2004 | 478 | 0.040 |
Why?
|
| Calcium | 3 | 1987 | 1546 | 0.040 |
Why?
|
| Lymphocyte Subsets | 2 | 1996 | 138 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 1999 | 44 | 0.040 |
Why?
|
| ATP Synthetase Complexes | 1 | 1998 | 5 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 1999 | 290 | 0.040 |
Why?
|
| Phosphotransferases (Phosphate Group Acceptor) | 1 | 1998 | 9 | 0.040 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 1998 | 24 | 0.040 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 1998 | 24 | 0.040 |
Why?
|
| Vascular Access Devices | 1 | 2019 | 51 | 0.040 |
Why?
|
| DNA, Protozoan | 1 | 1998 | 35 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 1999 | 62 | 0.040 |
Why?
|
| Interleukin-10 | 2 | 1999 | 485 | 0.040 |
Why?
|
| Radiography, Thoracic | 2 | 1992 | 461 | 0.040 |
Why?
|
| HL-60 Cells | 2 | 1996 | 302 | 0.040 |
Why?
|
| Fever | 3 | 1997 | 499 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 1990 | 57 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2014 | 496 | 0.040 |
Why?
|
| Endotoxins | 2 | 1997 | 96 | 0.040 |
Why?
|
| Mice | 17 | 1995 | 34391 | 0.040 |
Why?
|
| Imatinib Mesylate | 3 | 2009 | 1665 | 0.040 |
Why?
|
| Radiographic Image Enhancement | 2 | 1992 | 403 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 1999 | 118 | 0.040 |
Why?
|
| CD5 Antigens | 1 | 1999 | 115 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 1999 | 88 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2000 | 327 | 0.040 |
Why?
|
| Pseudogenes | 1 | 1998 | 81 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2000 | 402 | 0.040 |
Why?
|
| Sulfurtransferases | 1 | 1977 | 2 | 0.040 |
Why?
|
| Thiosulfate Sulfurtransferase | 1 | 1977 | 4 | 0.040 |
Why?
|
| Lyases | 1 | 1977 | 10 | 0.040 |
Why?
|
| Enzymes, Immobilized | 1 | 1977 | 10 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 1999 | 197 | 0.040 |
Why?
|
| Aminoacridines | 3 | 1986 | 23 | 0.040 |
Why?
|
| Membrane Potentials | 4 | 1987 | 425 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 5 | 1995 | 248 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2013 | 2325 | 0.040 |
Why?
|
| Safety | 1 | 2000 | 464 | 0.040 |
Why?
|
| Solutions | 1 | 1997 | 105 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 1997 | 128 | 0.040 |
Why?
|
| Platelet Transfusion | 2 | 2015 | 156 | 0.040 |
Why?
|
| Beijing | 1 | 2017 | 13 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1998 | 182 | 0.040 |
Why?
|
| Measles Vaccine | 1 | 1997 | 10 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 218 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 1998 | 226 | 0.040 |
Why?
|
| Databases, Factual | 3 | 2014 | 2236 | 0.040 |
Why?
|
| Plants | 1 | 1977 | 63 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 3583 | 0.040 |
Why?
|
| Protozoan Proteins | 1 | 1998 | 116 | 0.040 |
Why?
|
| Oxygen | 1 | 2002 | 755 | 0.040 |
Why?
|
| Benzamides | 3 | 2009 | 1834 | 0.040 |
Why?
|
| Cell Membrane | 2 | 1994 | 855 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 1998 | 216 | 0.040 |
Why?
|
| Bilirubin | 1 | 1998 | 221 | 0.040 |
Why?
|
| B-Lymphocytes | 4 | 1992 | 1306 | 0.040 |
Why?
|
| Alcoholism | 1 | 1980 | 308 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 250 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1990 | 2342 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1986 | 1396 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2010 | 2362 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 142 | 0.040 |
Why?
|
| Patient Admission | 1 | 1998 | 222 | 0.040 |
Why?
|
| Intensive Care Units | 2 | 2011 | 721 | 0.040 |
Why?
|
| Clone Cells | 4 | 1988 | 547 | 0.040 |
Why?
|
| Neoplasm Transplantation | 3 | 1995 | 1516 | 0.040 |
Why?
|
| Erythema Infectiosum | 1 | 2016 | 11 | 0.040 |
Why?
|
| Radioimmunodetection | 1 | 1996 | 16 | 0.040 |
Why?
|
| Aged, 80 and over | 11 | 2014 | 29996 | 0.040 |
Why?
|
| Contig Mapping | 1 | 2016 | 61 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2000 | 1030 | 0.040 |
Why?
|
| Infliximab | 2 | 2009 | 138 | 0.040 |
Why?
|
| Parvovirus B19, Human | 1 | 2016 | 39 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 94 | 0.040 |
Why?
|
| Adenosine Diphosphate | 1 | 1996 | 114 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 1998 | 576 | 0.040 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1996 | 14 | 0.040 |
Why?
|
| Photosystem II Protein Complex | 1 | 1996 | 3 | 0.040 |
Why?
|
| Cytochromes | 1 | 1996 | 10 | 0.040 |
Why?
|
| Spinacia oleracea | 1 | 1996 | 10 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2016 | 171 | 0.030 |
Why?
|
| Pigments, Biological | 1 | 1996 | 12 | 0.030 |
Why?
|
| Endogenous Retroviruses | 1 | 2016 | 42 | 0.030 |
Why?
|
| Prevalence | 2 | 2014 | 3272 | 0.030 |
Why?
|
| Chromatography | 1 | 1996 | 49 | 0.030 |
Why?
|
| Endotoxemia | 1 | 1997 | 61 | 0.030 |
Why?
|
| Mice, Nude | 2 | 1995 | 4303 | 0.030 |
Why?
|
| tert-Butylhydroperoxide | 1 | 1996 | 6 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 1996 | 46 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2003 | 1330 | 0.030 |
Why?
|
| Th2 Cells | 1 | 1997 | 256 | 0.030 |
Why?
|
| Aflatoxin M1 | 1 | 1995 | 2 | 0.030 |
Why?
|
| Aflatoxin B1 | 1 | 1995 | 7 | 0.030 |
Why?
|
| Oxidation-Reduction | 6 | 1996 | 719 | 0.030 |
Why?
|
| Myoglobin | 1 | 1996 | 116 | 0.030 |
Why?
|
| Hematology | 1 | 2017 | 101 | 0.030 |
Why?
|
| Respiration | 1 | 1998 | 448 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1996 | 86 | 0.030 |
Why?
|
| Dogs | 1 | 1997 | 1157 | 0.030 |
Why?
|
| Leukocyte Count | 3 | 1993 | 683 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2016 | 77 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 93 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2005 | 6103 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2002 | 2085 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 166 | 0.030 |
Why?
|
| Interferon Type I | 2 | 1995 | 250 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 203 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 612 | 0.030 |
Why?
|
| Bacteriophages | 1 | 2016 | 71 | 0.030 |
Why?
|
| Exercise | 1 | 2003 | 1186 | 0.030 |
Why?
|
| China | 1 | 2017 | 613 | 0.030 |
Why?
|
| Lung | 2 | 2001 | 3168 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1998 | 340 | 0.030 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1996 | 111 | 0.030 |
Why?
|
| Hemolysis | 1 | 1996 | 126 | 0.030 |
Why?
|
| Sinusitis | 1 | 1997 | 130 | 0.030 |
Why?
|
| Contraindications | 1 | 1995 | 151 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 1996 | 164 | 0.030 |
Why?
|
| Interferon-alpha | 2 | 1995 | 889 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 566 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 1995 | 104 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 1995 | 162 | 0.030 |
Why?
|
| Space-Time Clustering | 1 | 1995 | 2 | 0.030 |
Why?
|
| Erythrocytes | 2 | 1973 | 339 | 0.030 |
Why?
|
| Protein C | 1 | 1995 | 32 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1995 | 157 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 2633 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2002 | 1642 | 0.030 |
Why?
|
| Random Allocation | 1 | 1996 | 703 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 77 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 1996 | 227 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1997 | 843 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 101 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 1995 | 92 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1992 | 399 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 1998 | 582 | 0.030 |
Why?
|
| Medical Oncology | 2 | 2017 | 1424 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2016 | 162 | 0.030 |
Why?
|
| Cricetinae | 1 | 1996 | 702 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 1995 | 152 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 124 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 159 | 0.030 |
Why?
|
| Actuarial Analysis | 3 | 1997 | 159 | 0.030 |
Why?
|
| Phenotype | 4 | 2002 | 6255 | 0.030 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 1994 | 25 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 95 | 0.030 |
Why?
|
| Cyanobacteria | 1 | 1994 | 21 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1750 | 0.030 |
Why?
|
| Macrophages | 5 | 1990 | 1313 | 0.030 |
Why?
|
| Seafood | 1 | 2014 | 9 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1995 | 150 | 0.030 |
Why?
|
| Antibody-Producing Cells | 1 | 1973 | 15 | 0.030 |
Why?
|
| Meningitis, Viral | 1 | 1994 | 13 | 0.030 |
Why?
|
| RNA, Neoplasm | 4 | 1991 | 773 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1995 | 389 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 128 | 0.030 |
Why?
|
| Podophyllotoxin | 2 | 1999 | 63 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 333 | 0.030 |
Why?
|
| Serotyping | 1 | 2014 | 166 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 3 | 1992 | 429 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2001 | 1412 | 0.030 |
Why?
|
| Mediastinal Neoplasms | 1 | 1998 | 422 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 1998 | 445 | 0.030 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 1994 | 118 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 1994 | 128 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 646 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 833 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 1997 | 4976 | 0.030 |
Why?
|
| Gene Frequency | 1 | 1996 | 1165 | 0.030 |
Why?
|
| Monocytes | 2 | 1996 | 771 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 1995 | 640 | 0.030 |
Why?
|
| Isoenzymes | 2 | 1993 | 608 | 0.030 |
Why?
|
| Meningitis, Bacterial | 1 | 1994 | 89 | 0.030 |
Why?
|
| Critical Illness | 1 | 1998 | 717 | 0.030 |
Why?
|
| Cell Nucleus | 3 | 1987 | 1618 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 755 | 0.030 |
Why?
|
| Mice, Inbred Strains | 4 | 1986 | 518 | 0.030 |
Why?
|
| Candida albicans | 1 | 1994 | 176 | 0.030 |
Why?
|
| Peptides | 2 | 1996 | 1476 | 0.030 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 1992 | 7 | 0.030 |
Why?
|
| Microcomputers | 1 | 1992 | 36 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1993 | 127 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2012 | 23 | 0.030 |
Why?
|
| Antigens, Differentiation | 2 | 2008 | 237 | 0.030 |
Why?
|
| Seminal Vesicles | 2 | 1983 | 152 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 3448 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1992 | 165 | 0.030 |
Why?
|
| Catalysis | 2 | 1983 | 249 | 0.030 |
Why?
|
| Sheep | 2 | 1983 | 257 | 0.030 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 2 | 1999 | 111 | 0.030 |
Why?
|
| Blood Component Transfusion | 1 | 1992 | 90 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1993 | 225 | 0.030 |
Why?
|
| Sex Factors | 2 | 1995 | 2156 | 0.030 |
Why?
|
| Leukocytosis | 1 | 1992 | 111 | 0.030 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1991 | 25 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 1992 | 123 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 393 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1992 | 184 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1992 | 185 | 0.030 |
Why?
|
| Dexamethasone | 3 | 2009 | 1450 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1996 | 505 | 0.030 |
Why?
|
| Iceland | 1 | 2011 | 12 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1995 | 842 | 0.030 |
Why?
|
| Finland | 1 | 2011 | 55 | 0.030 |
Why?
|
| Norway | 1 | 2011 | 30 | 0.030 |
Why?
|
| Denmark | 1 | 2011 | 49 | 0.020 |
Why?
|
| Candidiasis | 1 | 1994 | 262 | 0.020 |
Why?
|
| APACHE | 1 | 2011 | 93 | 0.020 |
Why?
|
| Drosophila | 1 | 1997 | 839 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 147 | 0.020 |
Why?
|
| Leukemia P388 | 1 | 1991 | 25 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1992 | 231 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 654 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 672 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1992 | 215 | 0.020 |
Why?
|
| Leukemia L1210 | 1 | 1991 | 54 | 0.020 |
Why?
|
| Tyrosine | 1 | 1993 | 500 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 257 | 0.020 |
Why?
|
| Platelet Count | 1 | 1992 | 490 | 0.020 |
Why?
|
| Gene Deletion | 1 | 1996 | 1440 | 0.020 |
Why?
|
| Logistic Models | 1 | 1998 | 3450 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2010 | 50 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 109 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 635 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 1998 | 897 | 0.020 |
Why?
|
| Autoantigens | 1 | 1992 | 235 | 0.020 |
Why?
|
| Phosphotransferases | 1 | 1991 | 82 | 0.020 |
Why?
|
| Dithiothreitol | 1 | 1990 | 21 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 130 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 548 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1992 | 311 | 0.020 |
Why?
|
| Transfection | 1 | 1996 | 2934 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 56 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2011 | 178 | 0.020 |
Why?
|
| Introns | 1 | 1992 | 430 | 0.020 |
Why?
|
| Vitamin B Deficiency | 1 | 1990 | 1 | 0.020 |
Why?
|
| Hypoproteinemia | 1 | 1990 | 3 | 0.020 |
Why?
|
| Pellagra | 1 | 1990 | 2 | 0.020 |
Why?
|
| Vitamin K Deficiency | 1 | 1990 | 4 | 0.020 |
Why?
|
| Riboflavin Deficiency | 1 | 1990 | 8 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 1995 | 1016 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 2 | 1987 | 232 | 0.020 |
Why?
|
| Catalase | 2 | 1981 | 70 | 0.020 |
Why?
|
| Isoantigens | 1 | 1990 | 61 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 1995 | 3127 | 0.020 |
Why?
|
| Niacin | 1 | 1990 | 61 | 0.020 |
Why?
|
| Thymine | 1 | 1990 | 46 | 0.020 |
Why?
|
| Bacteremia | 1 | 1995 | 689 | 0.020 |
Why?
|
| Folic Acid Deficiency | 1 | 1990 | 54 | 0.020 |
Why?
|
| Epitopes | 1 | 1992 | 682 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 178 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2009 | 53 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 1992 | 1265 | 0.020 |
Why?
|
| Hydroxylation | 2 | 1980 | 62 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 1991 | 463 | 0.020 |
Why?
|
| Carbon Radioisotopes | 2 | 1986 | 116 | 0.020 |
Why?
|
| Lymphocyte Activation | 3 | 2006 | 1690 | 0.020 |
Why?
|
| Radiation Chimera | 3 | 1974 | 30 | 0.020 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 2 | 2001 | 86 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1995 | 1466 | 0.020 |
Why?
|
| Drug Costs | 1 | 2010 | 145 | 0.020 |
Why?
|
| Triazoles | 1 | 1993 | 618 | 0.020 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2009 | 68 | 0.020 |
Why?
|
| Benzylamines | 1 | 2009 | 103 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1989 | 286 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 2009 | 142 | 0.020 |
Why?
|
| Proteins | 1 | 1997 | 1953 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2009 | 119 | 0.020 |
Why?
|
| Models, Statistical | 1 | 1995 | 1177 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 1985 | 424 | 0.020 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2009 | 108 | 0.020 |
Why?
|
| Cachexia | 1 | 1990 | 162 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 1980 | 201 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2009 | 181 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 133 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 83 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 1988 | 292 | 0.020 |
Why?
|
| Chromatography, Liquid | 2 | 1979 | 350 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 211 | 0.020 |
Why?
|
| Lymphotoxin-alpha | 1 | 1987 | 27 | 0.020 |
Why?
|
| Naphthalimides | 1 | 1987 | 14 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1987 | 82 | 0.020 |
Why?
|
| Breast Neoplasms | 3 | 2005 | 15709 | 0.020 |
Why?
|
| Camptothecin | 1 | 1990 | 515 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1987 | 201 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 1487 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 882 | 0.020 |
Why?
|
| Mathematics | 1 | 1987 | 135 | 0.020 |
Why?
|
| Clinical Protocols | 2 | 1993 | 465 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 1987 | 254 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1992 | 1557 | 0.020 |
Why?
|
| Creatinine | 2 | 1996 | 538 | 0.020 |
Why?
|
| RNA | 1 | 1992 | 1010 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1958 | 0.020 |
Why?
|
| Ploidies | 1 | 1987 | 250 | 0.020 |
Why?
|
| Disease Progression | 3 | 2004 | 6694 | 0.020 |
Why?
|
| Organophosphonates | 1 | 1987 | 64 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 1996 | 4026 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 1986 | 90 | 0.020 |
Why?
|
| Autopsy | 1 | 1986 | 173 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2006 | 89 | 0.020 |
Why?
|
| Vinblastine | 1 | 1987 | 453 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1986 | 31 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1986 | 208 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 1975 | 84 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 1986 | 191 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1989 | 351 | 0.020 |
Why?
|
| Protein Binding | 2 | 1983 | 3438 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 596 | 0.020 |
Why?
|
| Dimethadione | 1 | 1985 | 2 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 758 | 0.020 |
Why?
|
| DNA Probes | 2 | 2000 | 217 | 0.020 |
Why?
|
| Onium Compounds | 1 | 1985 | 9 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1986 | 109 | 0.020 |
Why?
|
| Trityl Compounds | 1 | 1985 | 3 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 1985 | 77 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2005 | 87 | 0.020 |
Why?
|
| K562 Cells | 1 | 2006 | 339 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 1985 | 68 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 2559 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 1308 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2005 | 150 | 0.020 |
Why?
|
| Diploidy | 1 | 1995 | 112 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1990 | 856 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 216 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5724 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 2 | 2013 | 4980 | 0.020 |
Why?
|
| Nucleotidases | 2 | 1981 | 13 | 0.020 |
Why?
|
| Iron Radioisotopes | 2 | 1974 | 5 | 0.020 |
Why?
|
| Phorbols | 1 | 1984 | 9 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 2005 | 218 | 0.020 |
Why?
|
| Adenosine Deaminase | 2 | 1981 | 94 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4903 | 0.010 |
Why?
|
| Glycolysis | 1 | 1987 | 523 | 0.010 |
Why?
|
| Autoradiography | 2 | 1986 | 133 | 0.010 |
Why?
|
| Tritium | 2 | 1986 | 197 | 0.010 |
Why?
|
| Structure-Activity Relationship | 2 | 1986 | 935 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1992 | 2022 | 0.010 |
Why?
|
| Steroids | 1 | 2005 | 355 | 0.010 |
Why?
|
| Receptors, Complement | 1 | 1984 | 48 | 0.010 |
Why?
|
| Asparaginase | 1 | 1984 | 184 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 299 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1990 | 1082 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1984 | 227 | 0.010 |
Why?
|
| Adenine | 1 | 1987 | 639 | 0.010 |
Why?
|
| Leucovorin | 1 | 1984 | 333 | 0.010 |
Why?
|
| Dasatinib | 1 | 2007 | 862 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2004 | 312 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2006 | 573 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2004 | 169 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 1999 | 4231 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1995 | 189 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 236 | 0.010 |
Why?
|
| Naphthacenes | 1 | 1983 | 4 | 0.010 |
Why?
|
| Mitochondrial Swelling | 1 | 1983 | 10 | 0.010 |
Why?
|
| Genome, Plant | 1 | 2003 | 24 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1987 | 746 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1984 | 179 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 11572 | 0.010 |
Why?
|
| Fixatives | 1 | 1983 | 29 | 0.010 |
Why?
|
| Cortisone | 2 | 1973 | 18 | 0.010 |
Why?
|
| Iron Isotopes | 2 | 1973 | 3 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 2 | 1981 | 191 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1983 | 65 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2007 | 3263 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1982 | 673 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1986 | 730 | 0.010 |
Why?
|
| Time | 1 | 2003 | 179 | 0.010 |
Why?
|
| Chromosome Segregation | 1 | 2003 | 81 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 1983 | 116 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1994 | 7218 | 0.010 |
Why?
|
| Barium | 1 | 1982 | 26 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1984 | 171 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1996 | 300 | 0.010 |
Why?
|
| Kidney Medulla | 1 | 1982 | 43 | 0.010 |
Why?
|
| Lymph Nodes | 4 | 1974 | 2969 | 0.010 |
Why?
|
| Microsomes | 1 | 1982 | 66 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 336 | 0.010 |
Why?
|
| Tissue Distribution | 2 | 1986 | 877 | 0.010 |
Why?
|
| Methyldopa | 1 | 1981 | 5 | 0.010 |
Why?
|
| Nucleoside Deaminases | 1 | 1981 | 33 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1247 | 0.010 |
Why?
|
| DNA Replication | 1 | 1986 | 746 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 1230 | 0.010 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1981 | 31 | 0.010 |
Why?
|
| Thymus Gland | 2 | 1973 | 294 | 0.010 |
Why?
|
| Biomarkers | 1 | 1993 | 5055 | 0.010 |
Why?
|
| Chimera | 2 | 1993 | 144 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2006 | 608 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 1982 | 229 | 0.010 |
Why?
|
| Itraconazole | 1 | 2001 | 77 | 0.010 |
Why?
|
| Immunocompromised Host | 2 | 1997 | 697 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 7549 | 0.010 |
Why?
|
| Survivors | 1 | 2006 | 1035 | 0.010 |
Why?
|
| Chromosome Walking | 1 | 2000 | 4 | 0.010 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1995 | 505 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2001 | 320 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2006 | 798 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1979 | 97 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 1260 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2000 | 68 | 0.010 |
Why?
|
| Chromosome Disorders | 2 | 1995 | 417 | 0.010 |
Why?
|
| DNA Adducts | 1 | 1981 | 211 | 0.010 |
Why?
|
| Muramidase | 1 | 1980 | 108 | 0.010 |
Why?
|
| Kidney | 2 | 1997 | 2144 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1979 | 56 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 1981 | 284 | 0.010 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1999 | 16 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 301 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 1999 | 80 | 0.010 |
Why?
|
| Antibody Specificity | 2 | 1980 | 331 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1999 | 46 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1979 | 100 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1999 | 70 | 0.010 |
Why?
|
| Methods | 1 | 1979 | 190 | 0.010 |
Why?
|
| Whole-Body Counting | 1 | 1979 | 27 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1980 | 259 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1979 | 115 | 0.010 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1978 | 34 | 0.010 |
Why?
|
| Glutathione Peroxidase | 1 | 1978 | 62 | 0.010 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 1978 | 41 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1999 | 193 | 0.010 |
Why?
|
| Alkaline Phosphatase | 2 | 1996 | 204 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1999 | 143 | 0.010 |
Why?
|
| Phenolphthaleins | 1 | 1978 | 2 | 0.010 |
Why?
|
| Uridine Diphosphate | 1 | 1978 | 8 | 0.010 |
Why?
|
| Hymecromone | 1 | 1978 | 6 | 0.010 |
Why?
|
| Glucuronates | 1 | 1978 | 12 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 757 | 0.010 |
Why?
|
| Lactates | 1 | 1978 | 113 | 0.010 |
Why?
|
| Naphthols | 1 | 1978 | 25 | 0.010 |
Why?
|
| Serology | 1 | 1997 | 5 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1996 | 33 | 0.010 |
Why?
|
| Thy-1 Antigens | 1 | 1996 | 48 | 0.010 |
Why?
|
| Telomere | 1 | 2000 | 507 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1988 | 539 | 0.010 |
Why?
|
| Cysteine | 1 | 1977 | 214 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 1996 | 140 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1997 | 174 | 0.010 |
Why?
|
| Insulin | 1 | 1982 | 1446 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1975 | 23 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1997 | 488 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1980 | 677 | 0.010 |
Why?
|
| Vomiting | 1 | 1997 | 352 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 1997 | 221 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 176 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1996 | 179 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2000 | 1946 | 0.010 |
Why?
|
| Nausea | 1 | 1997 | 525 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 995 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1995 | 239 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 1995 | 175 | 0.010 |
Why?
|
| Pedigree | 1 | 1999 | 1884 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1996 | 477 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 2232 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 373 | 0.010 |
Why?
|
| Membranes | 1 | 1994 | 31 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1975 | 346 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1994 | 124 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2000 | 2231 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1994 | 82 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 1994 | 43 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 1973 | 9 | 0.010 |
Why?
|
| Hemagglutination Tests | 1 | 1973 | 33 | 0.010 |
Why?
|
| Electron Transport Complex IV | 1 | 1994 | 57 | 0.010 |
Why?
|
| Glass | 1 | 1973 | 30 | 0.010 |
Why?
|
| Premedication | 1 | 1994 | 134 | 0.010 |
Why?
|
| Dextrans | 1 | 1994 | 91 | 0.010 |
Why?
|
| Immune Sera | 1 | 1973 | 145 | 0.010 |
Why?
|
| Radiation Effects | 1 | 1973 | 20 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1997 | 1554 | 0.010 |
Why?
|
| Adsorption | 1 | 1973 | 46 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1993 | 119 | 0.010 |
Why?
|
| Free Radicals | 2 | 1985 | 62 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1974 | 266 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1993 | 152 | 0.010 |
Why?
|
| Interferons | 2 | 1987 | 289 | 0.010 |
Why?
|
| Chickens | 1 | 1973 | 528 | 0.010 |
Why?
|
| Nitriles | 1 | 1977 | 904 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1973 | 171 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1973 | 95 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1993 | 114 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 334 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1992 | 34 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 1992 | 31 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1993 | 328 | 0.010 |
Why?
|
| Blood Cells | 1 | 1993 | 128 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 2 | 1994 | 2344 | 0.010 |
Why?
|
| Glycosylation | 1 | 1993 | 212 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1996 | 405 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1989 | 4655 | 0.010 |
Why?
|
| Immunization | 1 | 1974 | 398 | 0.010 |
Why?
|
| Connective Tissue Diseases | 1 | 1992 | 49 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 1992 | 148 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 1997 | 591 | 0.010 |
Why?
|
| Radiography | 1 | 1996 | 1900 | 0.010 |
Why?
|
| Benz(a)Anthracenes | 1 | 1971 | 9 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1996 | 1070 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2000 | 3891 | 0.010 |
Why?
|
| Photography | 1 | 1992 | 138 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 1033 | 0.010 |
Why?
|
| Kanamycin Kinase | 1 | 1991 | 16 | 0.010 |
Why?
|
| Organ Transplantation | 1 | 1994 | 192 | 0.010 |
Why?
|
| Neomycin | 1 | 1991 | 37 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 1125 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1992 | 365 | 0.010 |
Why?
|
| Temperature | 1 | 1992 | 508 | 0.010 |
Why?
|
| Interleukin-1beta | 1 | 1992 | 301 | 0.010 |
Why?
|
| Mice, Inbred CBA | 2 | 1984 | 74 | 0.010 |
Why?
|
| 5'-Nucleotidase | 2 | 1981 | 62 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 4845 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1991 | 215 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1991 | 172 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1990 | 57 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1989 | 67 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1988 | 1063 | 0.010 |
Why?
|
| X-Ray Intensifying Screens | 1 | 1989 | 33 | 0.010 |
Why?
|
| Software | 1 | 1997 | 1326 | 0.010 |
Why?
|
| Thoracic Diseases | 1 | 1989 | 32 | 0.010 |
Why?
|
| Tretinoin | 1 | 1992 | 622 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 1990 | 74 | 0.010 |
Why?
|
| Urticaria Pigmentosa | 1 | 1989 | 2 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1989 | 274 | 0.010 |
Why?
|
| Ecchymosis | 1 | 1989 | 21 | 0.010 |
Why?
|
| Quality of Life | 1 | 2003 | 4583 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1993 | 1864 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1989 | 351 | 0.010 |
Why?
|
| Hemin | 1 | 1988 | 24 | 0.010 |
Why?
|
| Purpura | 1 | 1989 | 31 | 0.010 |
Why?
|
| Vasculitis | 1 | 1989 | 64 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1992 | 577 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1982 | 3347 | 0.000 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1992 | 674 | 0.000 |
Why?
|
| Crithidia | 1 | 1987 | 1 | 0.000 |
Why?
|
| Malates | 1 | 1987 | 7 | 0.000 |
Why?
|
| Pyruvates | 1 | 1987 | 28 | 0.000 |
Why?
|
| Complement System Proteins | 2 | 1980 | 137 | 0.000 |
Why?
|
| Proton-Translocating ATPases | 1 | 1987 | 28 | 0.000 |
Why?
|
| Aneuploidy | 1 | 1988 | 368 | 0.000 |
Why?
|
| Electron Transport | 1 | 1987 | 81 | 0.000 |
Why?
|
| Citrates | 1 | 1987 | 39 | 0.000 |
Why?
|
| Immunoblotting | 1 | 1989 | 882 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1987 | 126 | 0.000 |
Why?
|
| Glutamates | 1 | 1987 | 130 | 0.000 |
Why?
|
| Growth Inhibitors | 1 | 1987 | 149 | 0.000 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1987 | 190 | 0.000 |
Why?
|
| Superoxides | 1 | 1987 | 209 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1986 | 143 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1988 | 1165 | 0.000 |
Why?
|
| Phosphates | 1 | 1987 | 189 | 0.000 |
Why?
|
| Models, Biological | 2 | 1988 | 3242 | 0.000 |
Why?
|
| Thymidine | 1 | 1986 | 151 | 0.000 |
Why?
|
| Oxidative Phosphorylation | 1 | 1987 | 254 | 0.000 |
Why?
|
| Arabinofuranosylcytosine Triphosphate | 1 | 1985 | 75 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1987 | 310 | 0.000 |
Why?
|
| Horseradish Peroxidase | 1 | 1985 | 18 | 0.000 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1985 | 62 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1985 | 69 | 0.000 |
Why?
|
| Regeneration | 1 | 1988 | 279 | 0.000 |
Why?
|
| Gene Rearrangement | 1 | 1989 | 784 | 0.000 |
Why?
|
| Mice, Inbred A | 1 | 1984 | 31 | 0.000 |
Why?
|
| Macrophage-1 Antigen | 1 | 1984 | 51 | 0.000 |
Why?
|
| Interphase | 1 | 1984 | 146 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1987 | 862 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1982 | 181 | 0.000 |
Why?
|
| Mice, Obese | 1 | 1982 | 104 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1985 | 703 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1982 | 300 | 0.000 |
Why?
|
| Enzyme Inhibitors | 1 | 1990 | 1879 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1985 | 625 | 0.000 |
Why?
|
| Mycobacterium bovis | 1 | 1982 | 67 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1982 | 357 | 0.000 |
Why?
|
| Clinical Enzyme Tests | 1 | 1980 | 25 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1980 | 240 | 0.000 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1980 | 57 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1989 | 4745 | 0.000 |
Why?
|
| Formates | 1 | 1978 | 9 | 0.000 |
Why?
|
| Phenobarbital | 1 | 1978 | 48 | 0.000 |
Why?
|
| Chromatography, Gas | 1 | 1978 | 39 | 0.000 |
Why?
|
| Formaldehyde | 1 | 1978 | 114 | 0.000 |
Why?
|
| Glucose | 1 | 1982 | 1247 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1980 | 1327 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 1986 | 6925 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1971 | 130 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1971 | 383 | 0.000 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1971 | 494 | 0.000 |
Why?
|